Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) - Safety
Phase 3
Completed
- Conditions
- Hygiene
- Interventions
- Drug: Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
- Registration Number
- NCT00785148
- Lead Sponsor
- Sanofi
- Brief Summary
To prove the safety of the gynaecological formulation in normal conditions of use.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 31
Inclusion Criteria
- Integral skin test in the region,
- Use of cosmetic product of the same category
Exclusion Criteria
- Lactation or gestational risk or gestation
- Use of Anti-inflammatory, immunosuppression or anti-histaminic drugs
- Atopic antecedent or allergic to cosmetic product
- Active cutaneous disease in the evaluation area
- Diseases which cause immunology decrease, such as diabetes and HIV
- Endocrinal pathologies
- Intense solar exposure 15 days before the evaluation
- Treatment until four months before the selection
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
- Primary Outcome Measures
Name Time Method The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction. From treatment start to the end of study
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Sanofi-Aventis Administrative Office
🇧🇷Sao Paulo, Brazil